Introducing: Modern Retina

Article

Ophthalmology Times is pleased to introduce a new clinical and educational platform for retina specialists called Modern Retina.

Dear Ophthalmologists:

The mission of Ophthalmology Times is to be a physician-driven media brand that presents cutting-edge advancements from around the world in surgery, clinical diagnosis, drug therapy, and technology.

It is on this premise that Ophthalmology Times is pleased to introduce a new clinical and educational platform for retina specialists called Modern Retina.

Built upon the success of Ophthalmology Times, Modern Retina is a completely digital brand that will provide retinal physicians (and ophthalmologists with an interest in the segment) with the latest innovations in the areas of retinal surgery, clinical information, research, pharmaceutical advancements, technology, even practice management.

Modern Retina’s distinct Editorial Advisory Board will guide the editorial team to identify information needs and educational gaps to develop content that physicians can utilize for better patient care.

Please visit Modern Retina at www.modernretina.com. We welcome your feedback; you can email me at mark.dlugoss@ubm.com.

Sincerely,

Mark L. Dlugoss

Group Content Director

Modern Retina | Ophthalmology Times

                                                                                                                                                                    

 

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.